Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 38
1.
Brain Imaging Behav ; 11(6): 1652-1663, 2017 Dec.
Article En | MEDLINE | ID: mdl-27766586

Women with ovarian cancer often undergo chemotherapy involving multiple agents. However, little is known about treatment-related central neurotoxicity in this population. The goal of this cross-sectional study was to assess brain structure and function and neurocognitive abilities in patients with ovarian cancer following first-line chemotherapy. Eighteen patients with ovarian, peritoneal and fallopian tube cancer and eighteen healthy controls matched for gender, age and education participated in the study. The patients were evaluated 1-4 months following completion of first-line taxane/platinum chemotherapy. All participants underwent structural and functional magnetic resonance imaging (MRI), and completed neuropsychological tests of attention, memory and executive functions. Neuroimaging assessments included voxel-based morphometry (VBM) for measuring gray matter (GM) volume, and functional MRI (fMRI) during the N-back working memory task. The results of VBM showed that patients had significantly reduced GM volume compared to healthy controls in the right middle/superior frontal gyrus, and in the left supramarginal gyrus and left inferior parietal lobule. fMRI results indicated significantly decreased activation in patients relative to healthy controls in the left middle frontal gyrus and left inferior parietal lobule during the N-back task (1/2/3-back >0-back). There were no statistically significant differences between the two groups on the neuropsychological tests. This is the first study showing structural and functional alterations involving frontal and parietal regions in patients with ovarian cancer treated with first-line chemotherapy. These findings are congruent with studies involving women with breast cancer, and provide additional supporting evidence for central neurotoxicity associated with taxane/platinum chemotherapy.


Antineoplastic Agents/toxicity , Brain/diagnostic imaging , Brain/physiopathology , Ovarian Neoplasms/drug therapy , Adult , Aged , Antineoplastic Agents/therapeutic use , Brain/drug effects , Brain/pathology , Brain Mapping , Bridged-Ring Compounds/therapeutic use , Bridged-Ring Compounds/toxicity , Cohort Studies , Cross-Sectional Studies , Female , Gray Matter/diagnostic imaging , Gray Matter/drug effects , Gray Matter/pathology , Gray Matter/physiopathology , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Memory, Short-Term/physiology , Middle Aged , Neuropsychological Tests , Organ Size , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/physiopathology , Ovarian Neoplasms/psychology , Pilot Projects , Platinum Compounds/therapeutic use , Platinum Compounds/toxicity , Preliminary Data , Taxoids/therapeutic use , Taxoids/toxicity
2.
Brain Imaging Behav ; 10(2): 486-96, 2016 06.
Article En | MEDLINE | ID: mdl-26153467

Hematopoietic stem cell transplantation (HSCT) is often used in the treatment of hematologic disorders. Although it can be curative, the pre-transplant conditioning regimen can be associated with neurotoxicity. In this prospective study, we examined white matter (WM) integrity with diffusion tensor imaging (DTI) and neuropsychological functioning before and one year after HSCT in twenty-two patients with hematologic disorders and ten healthy controls evaluated at similar intervals. Eighteen patients received conditioning treatment with high-dose (HD) chemotherapy, and four had full dose total body irradiation (fTBI) and HD chemotherapy prior to undergoing an allogeneic or autologous HSCT. The results showed a significant decrease in mean diffusivity (MD) and axial diffusivity (AD) in diffuse WM regions one year after HSCT (p-corrected <0.05) in the patient group compared to healthy controls. At baseline, patients treated with allogeneic HSCT had higher MD and AD in the left hemisphere WM than autologous HSCT patients (p-corrected <0.05). One year post-transplant, patients treated with allogeneic HSCT had lower fractional anisotropy (FA) and higher radial diffusivity (RD) in the right hemisphere and left frontal WM compared to patients treated with autologous HSCT (p-corrected <0.05).There were modest but significant correlations between MD values and cognitive test scores, and these were greatest for timed tests and in projection tracts. Patients showed a trend toward a decline in working memory, and had lower cognitive test scores than healthy controls at the one-year assessment. The findings suggest a relatively diffuse pattern of alterations in WM integrity in adult survivors of HSCT.


Hematopoietic Stem Cell Transplantation/adverse effects , White Matter/pathology , Adult , Adult Stem Cells/physiology , Adult Stem Cells/transplantation , Aged , Anisotropy , Brain/pathology , Cognition/physiology , Cognition Disorders/physiopathology , Diffusion Tensor Imaging/methods , Female , Humans , Male , Middle Aged , Neuropsychological Tests , White Matter/anatomy & histology
4.
J Intern Med ; 275(3): 284-95, 2014 Mar.
Article En | MEDLINE | ID: mdl-24605809

Current treatment options for Alzheimer's disease (AD) are limited to medications that reduce dementia symptoms. Given the rapidly ageing populations in most areas of the world, new therapeutic interventions for AD are urgently needed. In recent years, a number of drug candidates targeting the amyloid-ß (Aß) peptide have advanced into clinical trials; however, most have failed because of safety issues or lack of efficacy. The Aß peptide is central to the pathogenesis, and immunotherapy against Aß has attracted considerable interest. It offers the possibility to reach the target with highly specific drugs. Active immunization and passive immunization have been the most widely studied approaches to immunotherapy of AD. A favourable aspect of active immunization is the capacity for a small number of vaccinations to generate a prolonged antibody response. A potential disadvantage is the variability in the antibody response across patients. The potential advantages of passive immunotherapy include the reproducible delivery of a known amount of therapeutic antibodies to the patient and rapid clearance of those antibodies if side effects develop. A disadvantage is the requirement for repeated infusions of antibodies over time. After more than a decade of research, anti-amyloid immunotherapy remains one of the most promising emerging strategies for developing disease-modifying treatments for AD. In this review, we examine the presently ongoing Aß-directed immunotherapies that have passed clinical development Phase IIa.


Alzheimer Disease , Alzheimer Vaccines/therapeutic use , Amyloid beta-Peptides , Immunotherapy , Alzheimer Disease/drug therapy , Alzheimer Disease/immunology , Alzheimer Disease/prevention & control , Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/immunology , Clinical Trials, Phase II as Topic , Humans , Immunization, Passive/methods , Immunotherapy/adverse effects , Immunotherapy/methods , Molecular Targeted Therapy , Treatment Outcome , Vaccination/methods
5.
Brain Imaging Behav ; 7(4): 478-90, 2013 Dec.
Article En | MEDLINE | ID: mdl-23329358

Hematopoietic stem cell transplantation (HSCT) is an efficacious treatment for many hematologic malignancies. However, the conditioning regimen of high-dose (HD) chemotherapy with or without total body irradiation (TBI) can be associated with neurotoxicity. In this prospective study, we used quantitative neuroimaging techniques to examine regional gray matter and ventricular volumes, and standardized neuropsychological tests to assess cognitive function before and 1 year after HSCT in 28 patients with hematologic malignancies and in ten healthy controls evaluated at similar intervals. Nineteen patients received conditioning treatment with HD chemotherapy alone and nine had both TBI and HD chemotherapy. There was a significant reduction in gray matter volume in the middle frontal gyrus bilaterally and in the left caudate nucleus in the patient group (all patients combined) but not among healthy controls over the 1-year follow-up period. There was a significant increase in left lateral ventricle volume and in total ventricle volume in the patient group, relative to healthy controls. Similar brain structural changes were seen for patients treated with HD chemotherapy alone. The neuropsychological results showed that 21% of patients could be classified as impaired at baseline. The Reliable Change Index suggested no significantly different rates of cognitive decline between patients and healthy controls. The findings suggest that HSCT patients may be at an increased risk for developing regional brain volume loss, and that subgroups may experience cognitive dysfunction prior to and 1 year following the transplant.


Adult Stem Cells/transplantation , Brain/pathology , Brain/physiopathology , Cognition Disorders/etiology , Cognition Disorders/physiopathology , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/physiopathology , Adult , Aged , Cognition , Cognition Disorders/pathology , Female , Hematologic Neoplasms/complications , Humans , Male , Middle Aged , Prospective Studies , Stem Cell Transplantation/adverse effects , Treatment Outcome
6.
Mol Psychiatry ; 18(8): 889-97, 2013 Aug.
Article En | MEDLINE | ID: mdl-22850627

Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer's disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States. We sought to determine whether latrepirdine (LAT)-stimulated amyloid precursor protein (APP) catabolism is at least partially attributable to regulation of macroautophagy, a highly conserved protein catabolism pathway that is known to be impaired in brains of patients with Alzheimer's disease (AD). We utilized several mammalian cellular models to determine whether LAT regulates mammalian target of rapamycin (mTOR) and Atg5-dependent autophagy. Male TgCRND8 mice were chronically administered LAT prior to behavior analysis in the cued and contextual fear conditioning paradigm, as well as immunohistological and biochemical analysis of AD-related neuropathology. Treatment of cultured mammalian cells with LAT led to enhanced mTOR- and Atg5-dependent autophagy. Latrepirdine treatment of TgCRND8 transgenic mice was associated with improved learning behavior and with a reduction in accumulation of Aß42 and α-synuclein. We conclude that LAT possesses pro-autophagic properties in addition to the previously reported pro-neurogenic properties, both of which are potentially relevant to the treatment and/or prevention of neurodegenerative diseases. We suggest that elucidation of the molecular mechanism(s) underlying LAT effects on neurogenesis, autophagy and behavior might warranty the further study of LAT as a potentially viable lead compound that might yield more consistent clinical benefit following the optimization of its pro-neurogenic, pro-autophagic and/or pro-cognitive activities.


Alzheimer Disease/drug therapy , Autophagy/drug effects , Cognition/drug effects , Indoles/pharmacology , Neuroprotective Agents/pharmacology , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Amyloid beta-Peptides/metabolism , Animals , Autophagy-Related Protein 5 , Brain/drug effects , Brain/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Indoles/therapeutic use , Mice , Mice, Transgenic , Microtubule-Associated Proteins/metabolism , Neuroprotective Agents/therapeutic use , Peptide Fragments/metabolism , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/metabolism , alpha-Synuclein/metabolism
7.
AJNR Am J Neuroradiol ; 34(6): 1168-74, 2013.
Article En | MEDLINE | ID: mdl-23257611

BACKGROUND AND PURPOSE: Accurate diagnosis of normal pressure hydrocephalus is challenging because the clinical symptoms and radiographic appearance of NPH often overlap those of other conditions, including age-related neurodegenerative disorders such as Alzheimer and Parkinson diseases. We hypothesized that radiologic differences between NPH and AD/PD can be characterized by a robust and objective MR imaging DTI technique that does not require intersubject image registration or operator-defined regions of interest, thus avoiding many pitfalls common in DTI methods. MATERIALS AND METHODS: We collected 3T DTI data from 15 patients with probable NPH and 25 controls with AD, PD, or dementia with Lewy bodies. We developed a parametric model for the shape of intracranial mean diffusivity histograms that separates brain and ventricular components from a third component composed mostly of partial volume voxels. To accurately fit the shape of the third component, we constructed a parametric function named the generalized Voss-Dyke function. We then examined the use of the fitting parameters for the differential diagnosis of NPH from AD, PD, and DLB. RESULTS: Using parameters for the MD histogram shape, we distinguished clinically probable NPH from the 3 other disorders with 86% sensitivity and 96% specificity. The technique yielded 86% sensitivity and 88% specificity when differentiating NPH from AD only. CONCLUSIONS: An adequate parametric model for the shape of intracranial MD histograms can distinguish NPH from AD, PD, or DLB with high sensitivity and specificity.


Brain/pathology , Hydrocephalus, Normal Pressure/diagnosis , Magnetic Resonance Imaging/methods , Models, Theoretical , Neurodegenerative Diseases/diagnosis , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Diagnosis, Differential , Female , Humans , Hydrocephalus, Normal Pressure/pathology , Hydrocephalus, Normal Pressure/physiopathology , Image Processing, Computer-Assisted/methods , Image Processing, Computer-Assisted/standards , Lewy Body Disease/diagnosis , Lewy Body Disease/pathology , Lewy Body Disease/physiopathology , Magnetic Resonance Imaging/standards , Male , Middle Aged , Neurodegenerative Diseases/pathology , Neurodegenerative Diseases/physiopathology , Parkinson Disease/diagnosis , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Reproducibility of Results , Sensitivity and Specificity
8.
Clin Exp Immunol ; 158 Suppl 1: 34-42, 2009 Dec.
Article En | MEDLINE | ID: mdl-19883422

Intravenous immunoglobulin (IVIg) is used increasingly in the management of patients with neurological conditions. The efficacy and safety of IVIg treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barré syndrome (GBS) have been established clearly in randomized controlled trials and summarized in Cochrane systematic reviews. However, questions remain regarding the dose, timing and duration of IVIg treatment in both disorders. Reports about successful IVIg treatment in other neurological conditions exist, but its use remains investigational. IVIg has been shown to be efficacious as second-line therapy in patients with dermatomyositis and suggested to be of benefit in some patients with polymyositis. In patients with inclusion body myositis, IVIg was not shown to be effective. IVIg is also a treatment option in exacerbations of myasthenia gravis. Studies with IVIg in patients with Alzheimer's disease have reported increased plasma anti-Abeta antibody titres associated with decreased Abeta peptide levels in the cerebrospinal fluid following IVIg treatment. These changes at the molecular level were accompanied by improved cognitive function, and large-scale randomized trials are under way.


Autoimmune Diseases of the Nervous System/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Alzheimer Disease/drug therapy , Guillain-Barre Syndrome/drug therapy , Humans , Myositis/drug therapy , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug therapy
9.
Acta Neurochir Suppl ; 95: 237-40, 2005.
Article En | MEDLINE | ID: mdl-16463856

The aim of this project was to develop evidenced based guidelines for the diagnosis and management of idiopathic normal pressure hydrocephalus (iNPH). An advisory panel consisting of the authors assisted by international experts met on several occasions and formulated preliminary guidelines for iNPH managemen. The authors developed evidentiary tables based on available literature from 1966 to the present. Additional meetings to refine the evidentiary tables and incorporate expert opinion when necessary resulted in the development the iNPH guidelines. Evidence based guidelines identifying the value of clinical examination, brain imaging, Tap Test, CSF drainage, ICP monitoring and Surgical Management in diagnosing and treating the iNPH patient were developed. These are the first international evidence based guidelines focused on iNPH. Class I data were scant and guidelines relied mostly on class II and III evidence. It became clear that more prospective randomized studies are needed to resolve some of the controversial issues such as iNPH classification and sensitivity of diagnostic tests for identifying shunt responsive iNPH.


Cerebrospinal Fluid Shunts/instrumentation , Cerebrospinal Fluid Shunts/standards , Hydrocephalus, Normal Pressure/diagnosis , Hydrocephalus, Normal Pressure/surgery , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/trends , Humans , Internationality , Practice Guidelines as Topic
10.
Clin Neuropsychol ; 17(2): 195-202, 2003 May.
Article En | MEDLINE | ID: mdl-13680426

Depression induced cognitive impairment, also referred to as the dementia syndrome of depression or pseudodementia, has been well characterized, yet the extent to which the more common mild depressive symptoms influence cognition has not been well studied. We sought to identify the influence of mild depressive symptoms on verbal fluency performance in a large sample of healthy community dwelling older adults. Letter and semantic fluency testing was conducted on 188 participants (ages 60-92 years) with no known history of neurologic or psychiatric disease. Depressive symptoms were assessed with the Geriatric Depression Scale (GDS). A total of 39 subjects obtained GDS scores consistent with mild depressive symptoms (GDS=10-19), and 149 subjects were identified as not depressed (GDS<10). ANOVA indicated that subjects with mild depressive symptoms performed significantly worse than normal controls on letter fluency (p<.05), but there was no significant difference between the groups on semantic fluency. Analysis of the nondepressed group stratified into young-old, middle-old, and oldest-old revealed a significant decline in semantic (p<.001) but not letter fluency with age. The nondepressed young-old showed the expected advantage for word list generation to semantic as compared to letter categories, yet this pattern was reversed in the older age groups, where letter fluency scores exceeded semantic fluency scores. Our results suggest that the presence of even mild depressive symptoms may confound using letter versus category discrepancies in the differential diagnosis of dementia. Further, our findings suggest that the commonly used strategy of examining letter-semantic fluency discrepancies may not be relevant for individuals of advanced age. Age-stratified normative data for fluency testing in older adults is also provided.


Cognition Disorders/diagnosis , Depressive Disorder/psychology , Verbal Behavior , Age Factors , Aged , Aged, 80 and over , Cognition Disorders/etiology , Depressive Disorder/complications , Female , Humans , Male , Middle Aged , Reference Values , Semantics
11.
Mol Psychiatry ; 7(7): 776-81, 2002.
Article En | MEDLINE | ID: mdl-12192622

Mutations in the presenilin-1 (PS-1) gene on chromosome 14 account for the majority of early-onset familial Alzheimer's disease (FAD) cases. To date, more than 90 mutations have been identified and, while most of these mutations are completely penetrant, the Glu318Gly mutation has been suggested to be partially penetrant. These findings indicate that it may play a similar role to apolipoprotein E (APOE)-epsilon4 by acting as a genetic risk factor for AD. In the current study, a total of 682 subjects were tested to assess the frequency of the Glu318Gly mutation in AD in the Australian population. The Glu318Gly mutation was identified in six sporadic late-onset AD patients, four FAD patients (unrelated) and in nine control subjects. The frequency of this mutation was highest in the familial AD group (8.7%) and lowest in control subjects (2.2%). When the mutation frequencies were compared, we found a statistically significant difference between the latter two groups (Fisher's exact test, P < 0.05). The genotype frequency of the Glu318Gly mutation in all AD cases and controls in the Australian population was 2.8%. This frequency is comparable to that observed for the Dutch population (3.2%), but not for the Finnish population (6.8% and 6.0%) or the Spanish population (5.3%). These findings show that the frequency of the Glu318Gly mutation is increased in FAD patients, suggesting a potential role as a genetic risk factor contributing to the pathogenesis of familial AD.


Alzheimer Disease/genetics , Membrane Proteins/genetics , Point Mutation , Adult , Age of Onset , Aged , Alzheimer Disease/epidemiology , Australia , Family Health , Female , Genetic Predisposition to Disease/epidemiology , Humans , Male , Middle Aged , Presenilin-1 , Risk Factors
12.
Neurology ; 56(9): 1143-53, 2001 May 08.
Article En | MEDLINE | ID: mdl-11342678

OBJECTIVE: To update the 1994 practice parameter for the diagnosis of dementia in the elderly. BACKGROUND: The AAN previously published a practice parameter on dementia in 1994. New research and clinical developments warrant an update of some aspects of diagnosis. METHODS: Studies published in English from 1985 through 1999 were identified that addressed four questions: 1) Are the current criteria for the diagnosis of dementia reliable? 2) Are the current diagnostic criteria able to establish a diagnosis for the prevalent dementias in the elderly? 3) Do laboratory tests improve the accuracy of the clinical diagnosis of dementing illness? 4) What comorbidities should be evaluated in elderly patients undergoing an initial assessment for dementia? RECOMMENDATIONS: Based on evidence in the literature, the following recommendations are made. 1) The DSM-III-R definition of dementia is reliable and should be used (Guideline). 2) The National Institute of Neurologic, Communicative Disorders and Stroke--AD and Related Disorders Association (NINCDS-ADRDA) or the Diagnostic and Statistical Manual, 3rd edition, revised (DSM-IIIR) diagnostic criteria for AD and clinical criteria for Creutzfeldt--Jakob disease (CJD) have sufficient reliability and validity and should be used (Guideline). Diagnostic criteria for vascular dementia, dementia with Lewy bodies, and frontotemporal dementia may be of use in clinical practice (Option) but have imperfect reliability and validity. 3) Structural neuroimaging with either a noncontrast CT or MR scan in the initial evaluation of patients with dementia is appropriate. Because of insufficient data on validity, no other imaging procedure is recommended (Guideline). There are currently no genetic markers recommended for routine diagnostic purposes (Guideline). The CSF 14-3-3 protein is useful for confirming or rejecting the diagnosis of CJD (Guideline). 4) Screening for depression, B(12) deficiency, and hypothyroidism should be performed (Guideline). Screening for syphilis in patients with dementia is not justified unless clinical suspicion for neurosyphilis is present (Guideline). CONCLUSIONS: Diagnostic criteria for dementia have improved since the 1994 practice parameter. Further research is needed to improve clinical definitions of dementia and its subtypes, as well as to determine the utility of various instruments of neuroimaging, biomarkers, and genetic testing in increasing diagnostic accuracy.


Dementia/diagnosis , Humans
13.
Neurosurgery ; 47(3): 651-7; discussion 657-8, 2000 Sep.
Article En | MEDLINE | ID: mdl-10981753

OBJECTIVE: To determine whether the cognitive status of professional football players varies as a function of age and apolipoprotein E (APOE) genotype. METHODS: Fifty-three active players underwent APOE and neuropsychological assessments. Players were grouped according to age (proxy indicator of high/low exposure to contact) and the presence/absence of at least one copy of the epsilon4 allele. Outcome measures were overall cognitive performance and scores in cognitive domains. RESULTS: As a group, older players possessing APOE epsilon4 exhibited significantly lower cognitive test scores than did all other players studied, including non-epsilon4-possessing players and younger epsilon4-carriers. Measures of general cognitive functioning, information-processing speed and accuracy, and attention were related to poorer performance among the epsilon4-carrying players. In an analysis of variance model, the interaction between APOE genotype and age was significant (P = 0.004). As determined using linear regression, age accounted for 34% of the variance in the memory index among APOE epsilon4-possessing players but did not contribute significantly to variance among the non-epsilon4-possessing players. Older APOE epsilon4-carriers were significantly overrepresented among players whose scores indicated possible cognitive impairment, with the criterion of performing two or more standard deviations below the general normal values in a summary index of general cognitive functioning. CONCLUSION: Older professional football players who possessed the APOE epsilon4 allele scored lower on cognitive tests than did players without this allele or less experienced players of any genotype. The cognitive status of professional athletes with repeated exposure to head trauma may therefore be influenced by age, inherited factors such as APOE genotype, and cumulative exposure to contact.


Apolipoproteins E/genetics , Athletic Injuries/diagnosis , Brain Injury, Chronic/diagnosis , Cognition Disorders/diagnosis , Football/injuries , Genotype , Neuropsychological Tests , Adult , Age Factors , Alleles , Apolipoprotein E4 , Athletic Injuries/genetics , Brain Damage, Chronic/diagnosis , Brain Damage, Chronic/genetics , Brain Injury, Chronic/genetics , Cognition Disorders/genetics , Genetic Carrier Screening , Humans , Male , Risk Factors
14.
Neurosurgery ; 47(3): 711-21; discussion 721-2, 2000 Sep.
Article En | MEDLINE | ID: mdl-10981759

OBJECTIVE: To evaluate an integrated battery of preoperative functional magnetic resonance imaging (fMRI) tasks developed to identify cortical areas associated with tactile, motor, language, and visual functions. METHODS: Sensitivity of each task was determined by the probability that a targeted region was activated for both healthy volunteers (n = 63) and surgical patients with lesions in these critical areas (n = 125). Accuracy of each task was determined by the correspondence between the fMRI maps and intraoperative electrophysiological measurements, including somatosensory evoked potentials (n = 16), direct cortical stimulation (n = 9), and language mapping (n = 5), and by preoperative Wada tests (n = 13) and visual field examinations (n = 6). RESULTS: For healthy volunteers, the overall sensitivity was 100% for identification of the central sulcus, visual cortex, and putative Wernicke's area, and 93% for the putative Broca's area (dominant hemisphere). For patients with tumors affecting these regions of interest, task sensitivity was 97% for identification of the central sulcus, 100% for the visual cortex, 91% for the putative Wernicke's area, and 77% for the putative Broca's area. These sensitivities were enhanced by the use of multiple tasks to target related functions. Concordance of the fMRI maps and intraoperative electrophysiological measurements was observed whenever both techniques yielded maps and Wada and visual field examinations were consistent with fMRI results. CONCLUSION: This integrated fMRI task battery offers standardized and noninvasive preoperative maps of multiple critical functions to facilitate assessment of surgical risk, planning of surgical routes, and direction of conventional, intraoperative electrophysiological procedures. Thus, a greater range of structural and functional relationships is brought to bear in the service of optimal outcomes for neurosurgery.


Brain Diseases/surgery , Brain Mapping , Cerebral Cortex/physiopathology , Language , Magnetic Resonance Imaging , Motor Activity/physiology , Preoperative Care , Touch/physiology , Vision, Ocular/physiology , Adolescent , Adult , Aged , Brain Diseases/physiopathology , Cerebral Cortex/surgery , Child , Dominance, Cerebral , Female , Humans , Male , Middle Aged , Monitoring, Intraoperative , Reference Values , Sensitivity and Specificity
15.
Am J Pathol ; 156(1): 15-20, 2000 Jan.
Article En | MEDLINE | ID: mdl-10623648

Alzheimer's disease (AD) is characterized by the deposition of senile plaques (SPs) and neurofibrillary tangles (NFTs) in vulnerable brain regions. SPs are composed of aggregated beta-amyloid (Abeta) 40/42(43) peptides. Evidence implicates a central role for Abeta in the pathophysiology of AD. Mutations in betaAPP and presenilin 1 (PS1) lead to elevated secretion of Abeta, especially the more amyloidogenic Abeta42. Immunohistochemical studies have also emphasized the importance of Abeta42 in initiating plaque pathology. Cell biological studies have demonstrated that Abeta is generated intracellularly. Recently, endogenous Abeta42 staining was demonstrated within cultured neurons by confocal immunofluorescence microscopy and within neurons of PS1 mutant transgenic mice. A central question about the role of Abeta in disease concerns whether extracellular Abeta deposition or intracellular Abeta accumulation initiates the disease process. Here we report that human neurons in AD-vulnerable brain regions specifically accumulate gamma-cleaved Abeta42 and suggest that this intraneuronal Abeta42 immunoreactivity appears to precede both NFT and Abeta plaque deposition. This study suggests that intracellular Abeta42 accumulation is an early event in neuronal dysfunction and that preventing intraneuronal Abeta42 aggregation may be an important therapeutic direction for the treatment of AD.


Amyloid beta-Peptides/metabolism , Brain/metabolism , Neurons/metabolism , Peptide Fragments/metabolism , Adult , Aged , Aged, 80 and over , Brain/pathology , Cadaver , Cognition Disorders/metabolism , Cognition Disorders/pathology , Dementia/metabolism , Dementia/pathology , Dementia/psychology , Down Syndrome/metabolism , Down Syndrome/pathology , Humans , Immunohistochemistry , Infant , Middle Aged , Neurofibrillary Tangles/pathology , Plaque, Amyloid/pathology , Reference Values
16.
Cereb Cortex ; 10(1): 2-22, 2000 Jan.
Article En | MEDLINE | ID: mdl-10639391

Functional neuroimaging, psychophysical and electrophysiological investigations were performed in a patient with non-decussating retinal-fugal fibre syndrome, an inborn achiasmatic state in which the retinal projections of each eye map entirely to the ipsilateral primary visual cortex. Functional magnetic resonance imaging (fMRI) studies showed that for monocularly presented simple visual stimuli, only the ipsilateral striate cortex was activated. Within each hemisphere's striate cortex, the representation of the two hemifields overlapped extensively. Despite this gross miswiring, visual functions that require precise geometrical information (such as vernier acuity) were normal, and there was no evidence for the confounding of visual information between the overlapping ipsi-lateral and contralateral representations. Contrast sensitivity and velocity judgments were abnormal, but their dependence on the orientation and velocity of the targets suggests that this deficit was due to ocular instabilities, rather than the miswiring per se. There were no asymmetries in performance observed in visual search, visual naming or illusory contour perception. fMRI analysis of the latter two tasks under monocular viewing conditions indicated extensive bilateral activation of striate and prestriate areas. Thus, the remarkably normal visual behavior achieved by this patient is a result of both the plasticity of visual pathways, and efficient transfer of information between the hemispheres.


Optic Chiasm/abnormalities , Optic Nerve Diseases/diagnosis , Optic Nerve Diseases/physiopathology , Retina/physiopathology , Visual Cortex/physiopathology , Visual Perception , Adolescent , Brain Mapping , Contrast Sensitivity/physiology , Electroencephalography , Female , Functional Laterality , Humans , Infant , Magnetic Resonance Imaging , Motion Perception/physiology , Neuronal Plasticity , Photic Stimulation , Syndrome , Twins, Dizygotic , Visual Cortex/pathology , Visual Pathways/pathology , Visual Pathways/physiopathology
17.
Am J Manag Care ; 6(22 Suppl): S1111-8; discussion S1119-24, 2000 Dec.
Article En | MEDLINE | ID: mdl-11142176

In current practice, the diagnosis of Alzheimer's disease is often delayed for several years after the initial onset of symptoms. Earlier diagnosis is desirable for several reasons. It allows the patient, family, and clinician to plan more effectively for the future, reduces the likelihood of catastrophic events such as motor vehicle accidents, and permits more effective administration of medications to delay symptom progression. Early detection of dementia can improve the quality of life for the patient and the caregiver and ultimately reduce total care expenditures by delaying the time to nursing home admission and other costly outcomes.


Alzheimer Disease/diagnosis , Aged , Alzheimer Disease/economics , Alzheimer Disease/physiopathology , Caregivers , Cognition Disorders/diagnosis , Cost Savings , Disease Progression , Health Expenditures/statistics & numerical data , Humans , Quality of Life , United States
18.
Ann Neurol ; 45(1): 48-53, 1999 Jan.
Article En | MEDLINE | ID: mdl-9894876

The mitochondrial alpha-ketoglutarate dehydrogenase complex (KGDHC) is deficient in Alzheimer's disease (AD). The DLST gene encodes the core, dihydrolipoyl succinyltransferase (DLST) component of KGDHC, and recent reports indicate an association between polymorphisms of DLST and AD in both white and Japanese patients. We therefore examined the relationship between AD and the DLST and apolipoprotein E (APOE) genes in elderly (89 +/- 7 years) AD patients, in whom the epsilon4 allele of APOE (APOE4) is a weak risk factor for AD. Polymorphisms of DLST (A19,117G and T19,183C), shown to be of interest in previous studies, were analyzed by restriction fragment length polymorphism analysis after polymerase chain reaction amplification. In a series of 429 white subjects from two Jewish nursing homes, an association of APOE4 with AD was found only in patients homozygous for the G,C allele of DLST. Similar relationships occurred in the "very elderly" (> or =85 years, n = 302) subgroup of this series, and also in an autopsy series (n = 225) that included white subjects from the Jewish nursing homes as well as other white subjects. These findings suggest a relationship between APOE4 and a DLST locus in the pathogenesis of AD in very elderly subjects.


Acyltransferases/genetics , Alzheimer Disease/epidemiology , Alzheimer Disease/genetics , Age Factors , Aged , Aged, 80 and over , Alleles , Apolipoprotein E4 , Apolipoproteins E/genetics , Female , Genotype , Humans , Male , Polymorphism, Genetic , Restriction Mapping , Risk Factors
19.
Stereotact Funct Neurosurg ; 72(2-4): 95-102, 1999.
Article En | MEDLINE | ID: mdl-10853058

Although the correspondence between functional-magnetic resonance imaging (fMRI) representations of the sensorimotor cortex and intraoperative electrophysiology (including somatosensory evoked potential, SSEP, recordings and direct cortical stimulation) has been reported, a similar correspondence between fMRI and intraoperative localization of the language-sensitive cortex is not as well established. The aim of the present study was to evaluate the concordance between fMRI and intraoperative electrophysiology with respect to the localization of the language-sensitive and sensorimotor cortices. We present the results of 21 patients who underwent language and sensorimotor mapping by fMRI and intraoperative electrophysiology including SSEP recordings (n = 21), direct cortical stimulation of motor cortex (n = 15) and direct cortical stimulation of Broca's and Wernicke's area (n = 5). When responses were obtained with both methods, localization of function concurred in all cases. These observations suggest that fMRI represents a reliable preoperative tool for the identification of language-sensitive areas.


Brain Mapping , Evoked Potentials, Somatosensory , Frontal Lobe/physiology , Language , Magnetic Resonance Imaging , Temporal Lobe/physiology , Adolescent , Adult , Aged , Child , Electric Stimulation , Female , Frontal Lobe/anatomy & histology , Frontal Lobe/surgery , Humans , Intraoperative Period , Male , Middle Aged , Neuropsychological Tests , Parietal Lobe/physiopathology , Parietal Lobe/surgery , Preoperative Care/methods , Supratentorial Neoplasms/surgery , Temporal Lobe/anatomy & histology , Temporal Lobe/physiopathology , Temporal Lobe/surgery , Thalamus/physiopathology , Thalamus/surgery
20.
J Neurochem ; 71(5): 1920-5, 1998 Nov.
Article En | MEDLINE | ID: mdl-9798916

Studies of processing of the Alzheimer beta-amyloid precursor protein (betaAPP) have been performed to date mostly in continuous cell lines and indicate the existence of two principal metabolic pathways: the "beta-secretase" pathway, which generates beta-amyloid (A beta(1-40/42); approximately 4 kDa), and the "alpha-secretase" pathway, which generates a smaller fragment, the "p3" peptide (A beta(17-40/42); approximately 3 kDa). To determine whether similar processing events underlie betaAPP metabolism in neurons, media were examined following conditioning by primary neuronal cultures derived from embryonic day 17 rats. Immunoprecipitates of conditioned media derived from [35S]methionine pulse-labeled primary neuronal cultures contained 4- and 3-kDa A beta-related species. Radiosequencing analysis revealed that the 4-kDa band corresponded to conventional A beta beginning at position A beta(Asp1), whereas both radiosequencing and immunoprecipitation-mass spectrometry analyses indicated that the 3-kDa species in these conditioned media began with A beta(Glu11) at the N terminus, rather than A beta(Leu17) as does the conventional p3 peptide. Either activation of protein kinase C or inhibition of protein phosphatase 1/2A increased soluble betaAPP(alpha) release and decreased generation of both the 4-kDa A beta and the 3-kDa N-truncated A beta. Unlike results obtained with continuously cultured cells, protein phosphatase 1/2A inhibitors were more potent at reducing A beta secretion by neurons than were protein kinase C activators. These data indicate that rodent neurons generate abundant A beta variant peptides and emphasize the role of protein phosphatases in modulating neuronal A beta generation.


Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/metabolism , Genetic Variation/physiology , Neurons/physiology , Amino Acid Sequence , Animals , Cells, Cultured , Mice , Molecular Sequence Data , Molecular Weight , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Rats , Rats, Sprague-Dawley , Tumor Cells, Cultured
...